Marcus A. Neubauer

2.5k total citations
66 papers, 1.9k citations indexed

About

Marcus A. Neubauer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Marcus A. Neubauer has authored 66 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 32 papers in Pulmonary and Respiratory Medicine and 17 papers in Economics and Econometrics. Recurrent topics in Marcus A. Neubauer's work include Lung Cancer Treatments and Mutations (28 papers), Economic and Financial Impacts of Cancer (17 papers) and Colorectal Cancer Treatments and Studies (15 papers). Marcus A. Neubauer is often cited by papers focused on Lung Cancer Treatments and Mutations (28 papers), Economic and Financial Impacts of Cancer (17 papers) and Colorectal Cancer Treatments and Studies (15 papers). Marcus A. Neubauer collaborates with scholars based in United States, United Kingdom and France. Marcus A. Neubauer's co-authors include J. Russell Hoverman, Craig H. Reynolds, Donald Richards, Alexander I. Spira, Michael Kolodziej, Cynthia S. Johnson, Angela White, Nasser H. Hanna, Roy Beveridge and Nicholas J. Robert and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Marcus A. Neubauer

64 papers receiving 1.8k citations

Peers

Marcus A. Neubauer
Gennaro Daniele Italy
Gilberto Lopes United States
Maria Carmela Piccirillo Italy
Jane Bryce Italy
Ali McBride United States
Marjorie G. Zauderer United States
Harpreet Singh United States
Monique M.E.M. Bos Netherlands
Aakash Desai United States
Jeffrey P. Hodge United States
Gennaro Daniele Italy
Marcus A. Neubauer
Citations per year, relative to Marcus A. Neubauer Marcus A. Neubauer (= 1×) peers Gennaro Daniele

Countries citing papers authored by Marcus A. Neubauer

Since Specialization
Citations

This map shows the geographic impact of Marcus A. Neubauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcus A. Neubauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcus A. Neubauer more than expected).

Fields of papers citing papers by Marcus A. Neubauer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marcus A. Neubauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcus A. Neubauer. The network helps show where Marcus A. Neubauer may publish in the future.

Co-authorship network of co-authors of Marcus A. Neubauer

This figure shows the co-authorship network connecting the top 25 collaborators of Marcus A. Neubauer. A scholar is included among the top collaborators of Marcus A. Neubauer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcus A. Neubauer. Marcus A. Neubauer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Butrynski, James E., John C. Paschold, Patrick J. Ward, et al.. (2024). Biomarker testing in early-stage NSCLC: Results from the MYLUNG Consortium.. Journal of Clinical Oncology. 42(16_suppl). 8047–8047. 1 indexed citations
2.
Robert, Nicholas J., Janet L. Espirito, Liwei Chen, et al.. (2022). Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network. Lung Cancer. 166. 197–204. 45 indexed citations
3.
Robert, Nicholas J., Janet L. Espirito, Li-Wei Chen, et al.. (2021). Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices.. Journal of Clinical Oncology. 39(15_suppl). 9004–9004. 33 indexed citations
4.
Hoverman, J. Russell, et al.. (2020). Hospice or Hospital: The Costs of Dying of Cancer in the Oncology Care Model. SHILAP Revista de lepidopterología. 1(1). 92–96. 10 indexed citations
5.
Wilfong, Lalan S., et al.. (2016). Changing physician compensation and implementing new technology to enhance pathways compliance.. Journal of Clinical Oncology. 34(7_suppl). 187–187. 1 indexed citations
6.
Kim, Edward S., Marcus A. Neubauer, Allen Lee Cohn, et al.. (2013). Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. The Lancet Oncology. 14(13). 1326–1336. 50 indexed citations
7.
Spira, Alexander I., Nicholas Iannotti, Michael A. Savin, et al.. (2011). A Phase II Study of Eribulin Mesylate (E7389) in Patients With Advanced, Previously Treated Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 13(1). 31–38. 26 indexed citations
8.
Cohn, Allen Lee, Pankaj Khandelwal, David A. Smith, et al.. (2011). An Open-label, Single-arm, Phase 2 Trial of Panitumumab Plus FOLFIRI as Second-line Therapy in Patients with Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 10(3). 171–177. 33 indexed citations
9.
10.
Galsky, Matthew D., Daniel D. Von Hoff, Marcus A. Neubauer, et al.. (2010). Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Investigational New Drugs. 30(2). 695–701. 52 indexed citations
11.
Pippen, John, Anthony Elias, Marcus A. Neubauer, et al.. (2010). A Phase II Trial of Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer Who Have Received Prior Taxane Therapy. Clinical Breast Cancer. 10(2). 148–153. 10 indexed citations
12.
Reynolds, Craig H., et al.. (2008). Phase III open-label comparison of gemcitabine/oxaliplatin versus paclitaxel/carboplatin as first line therapy for advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 26(15_suppl). 8024–8024. 2 indexed citations
13.
Socinski, Mark A., Robert N. Raju, Marcus A. Neubauer, et al.. (2008). Pemetrexed in Relapsed Small-Cell Lung Cancer and the Impact of Shortened Vitamin Supplementation Lead-In Time: Results of a Phase II Trial. Journal of Thoracic Oncology. 3(11). 1308–1316. 20 indexed citations
14.
15.
Whitehead, Robert P., Sheryl McCoy, John S. Macdonald, et al.. (2006). Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: A Southwest Oncology Group study. Investigational New Drugs. 24(4). 335–341. 11 indexed citations
16.
Kolodziej, Michael, Marcus A. Neubauer, Steven R. Rousey, et al.. (2006). Phase II Trial of Docetaxel/Capecitabine in Hormone-Refractory Prostate Cancer. Clinical Genitourinary Cancer. 5(2). 155–161. 11 indexed citations
17.
Richards, Donald, Paul Richards, David Bodkin, Marcus A. Neubauer, & F. B. Oldham. (2005). Efficacy and Safety of Paclitaxel Poliglumex as First-Line Chemotherapy in Patients at High Risk with Advanced-Stage Non–Small-Cell Lung Cancer: Results of a Phase II Study. Clinical Lung Cancer. 7(3). 215–220. 23 indexed citations
18.
Neubauer, Marcus A., et al.. (2005). Results of a Phase II Trial of Gemcitabine in Patients with Non–Small-Cell Lung Cancer and a Performance Status of 2. Clinical Lung Cancer. 6(4). 245–249. 12 indexed citations
19.
Socinski, Mark A., Marcus A. Neubauer, Steven J. Ketchel, et al.. (2003). Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer. Lung Cancer. 40(1). 91–97. 7 indexed citations
20.
Staszewski, Schlomo, et al.. (1983). [Toxic shock syndrome. Description of 2 cases from the Frankfurt district].. PubMed. 125(11). 219–20. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gennaro Daniele Breakdown of academic impact, for papers by Gilberto Lopes Breakdown of academic impact, for papers by Maria Carmela Piccirillo Breakdown of academic impact, for papers by Jane Bryce Breakdown of academic impact, for papers by Ali McBride Breakdown of academic impact, for papers by Marjorie G. Zauderer Breakdown of academic impact, for papers by Harpreet Singh Breakdown of academic impact, for papers by Monique M.E.M. Bos Breakdown of academic impact, for papers by Aakash Desai Breakdown of academic impact, for papers by Jeffrey P. Hodge
Rankless by CCL
2026